These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31795447)

  • 1. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
    Mpilla G; Aboukameel A; Muqbil I; Kim S; Beydoun R; Philip PA; Mohammad RM; Kamgar M; Shidham V; Senapedis W; Baloglu E; Li J; Dyson G; Xue Y; El-Rayes B; Azmi AS
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31795447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
    Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
    Khan HY; Uddin MH; Balasubramanian SK; Sulaiman N; Iqbal M; Chaker M; Aboukameel A; Li Y; Senapedis W; Baloglu E; Mohammad RM; Zonder J; Azmi AS
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
    Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
    Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of NAMPT by PAK4 Inhibitors.
    Wang Y; Minden A
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
    Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
    Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
    Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
    Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer.
    Kudo K; Greer YE; Yoshida T; Harrington BS; Korrapati S; Shibuya Y; Henegar L; Kopp JB; Fujii T; Lipkowitz S; Annunziata CM
    Cancer Gene Ther; 2024 May; 31(5):721-735. PubMed ID: 38424218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the vulnerability to NAD
    Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
    Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
    Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
    Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
    Mitchell S; Zhang P; Cannon M; Beaver L; Lehman A; Harrington B; Sampath D; Byrd JC; Lapalombella R
    J Hematol Oncol; 2021 Jun; 14(1):101. PubMed ID: 34187548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
    Okumura S; Sasaki T; Minami Y; Ohsaki Y
    J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
    Mohammad RM; Li Y; Muqbil I; Aboukameel A; Senapedis W; Baloglu E; Landesman Y; Philip PA; Azmi AS
    Small GTPases; 2019 Sep; 10(5):367-377. PubMed ID: 28641032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
    Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
    Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer.
    Trott JF; Aboud OA; McLaughlin B; Anderson KL; Modiano JF; Kim K; Jen KY; Senapedis W; Chang H; Landesman Y; Baloglu E; Pili R; Weiss RH
    Kidney360; 2020 May; 1(5):376-388. PubMed ID: 35224510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
    Mitchell SR; Larkin K; Grieselhuber NR; Lai TH; Cannon M; Orwick S; Sharma P; Asemelash Y; Zhang P; Goettl VM; Beaver L; Mims A; Puduvalli VK; Blachly JS; Lehman A; Harrington B; Henderson S; Breitbach JT; Williams KE; Dong S; Baloglu E; Senapedis W; Kirschner K; Sampath D; Lapalombella R; Byrd JC
    Blood Adv; 2019 Feb; 3(3):242-255. PubMed ID: 30692102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
    Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
    Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.
    Espindola-Netto JM; Chini CCS; Tarragó M; Wang E; Dutta S; Pal K; Mukhopadhyay D; Sola-Penna M; Chini EN
    Oncotarget; 2017 Oct; 8(49):85054-85067. PubMed ID: 29156703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
    Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
    Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
    Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
    Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.